Article
Pharma In Brief - Supreme Court Of Canada Grants Apotex Leave To Appeal (Again) In Regard To The PLAVIX® Patent
On January 30, 2014, the Supreme Court of Canada ("SCC") granted Apotex Inc., et al. ("Apotex") leave to appeal the July 24, 2013 Federal Court of Appeal order declaring Canadian Patent No. 1,336,777 ("‘777 Patent") to be valid and infringed ("FCA Decision").
Norton Rose Fulbright Canada LLP
